Persistent inflammatory activation in people living with HIV. Involvement in atherosclerosis

Background An increased prevalence of atherosclerosis has been observed in people living with HIV (PLWH). This study aimed to analyze levels of inflammatory, immune, endothelial, platelet, and coagulation parameters, as well as their relationship with subclinical atherosclerosis. Methods A total of 120 PLWH with chronic infection and undetectable HIV load, along with 30 age- and sex-matched controls (HIV-uninfected individuals), were selected. Serum levels of proinflammatory molecules, including interleukin 6 (IL-6), soluble CD163, and high-sensitivity C-reactive protein, were measured. Additionally, neutrophil extracellular traps (NET)-derived parameters (anti-nucleosome antibody titers and myeloperoxidase concentrations), activated T lymphocytes, endothelial (E-selectin, vascular cell adhesion molecule 1), platelet (P-selectin, Platelet factor 4) and coagulation (D-dimer) markers were assessed. Cardiovascular risk factors were evaluated using the REGICOR and ASCVD risk estimators. In a subset of 61 individuals (18 controls and 43 PLWH), subclinical atherosclerosis was assessed by carotid Doppler ultrasound. Results Levels of IL-6, sCD163, anti-nucleosome antibodies, and activated T lymphocytes were elevated in PLWH compared to controls. Likewise, serum levels of platelet factor 4 and D-dimer were higher in PLWH. Those PLWH with carotid atherosclerotic lesions exhibited higher REGICOR and ASCVD scores, as well as elevated IL-6 concentrations, compared to those PLWH without carotid atherosclerotic lesions. Multivariable analysis identified the REGICOR score and IL-6 serum levels as independent factors associated with atherosclerosis. Conclusion People living with HIV with long-term viral load control exhibit increased levels of inflammatory, immune, platelet and coagulation markers. Subclinical atherosclerosis in this population is independently influenced by both classic cardiovascular risk factors and inflammatory activation.

• Publication year

  2025

• Venue

  Frontiers in Medicine

• Publication date

  2025-07-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fmed.2025.1621765PMID 40718411PMCID 12289632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers of inflammation and coagulation predict non‐AIDS‐defining events in a prospective cohort of virologically suppressed people living with HIV

  2025cited by this paper
• Association of HIV and HCV Infection With Carotid Artery Plaque Echomorphology in the MACS/WIHS Combined Cohort Study

  2024cited by this paper
• Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease

  2024cited by this paper
• Platelet factor 4(PF4) and its multiple roles in diseases.

  2023cited by this paper
• 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).

  2023cited by this paper
• Low-density granulocytes display immature cells with enhanced NET formation in people living with HIV

  2023cited by this paper
• Expression profile of microRNAs related with viral infectivity, inflammatory response, and immune activation in people living with HIV

  2023cited by this paper
• HIV-RELATED ATHEROSCLEROSIS: STATE-OF-THE-ART-REVIEW.

  2023cited by this paper
• HIV and cardiovascular disease: the role of inflammation

  2022cited by this paper
• Endothelial Dysfunction and Its Clinical Implications

  2021cited by this paper
• Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equations

  2021cited by this paper
• Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

  2021cited by this paper
• Deoxyribonucleases and Their Applications in Biomedicine

  2020cited by this paper
• HIV infection and coronary heart disease: mechanisms and management

  2019cited by this paper
• Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART

  2019cited by this paper
• Viral infection and atherosclerosis

  2018cited by this paper
• Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2

  2018cited by this paper
• Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems

  2017cited by this paper
• Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection.

  2016cited by this paper
• Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy

  2016cited by this paper
• Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study.

  2016cited by this paper
• The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV‐1 infection

  2015cited by this paper
• Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study

  2015cited by this paper
• Immune Activation Response in Chronic HIV-Infected Patients: Influence of Hepatitis C Virus Coinfection

  2015cited by this paper
• Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.

  2015cited by this paper
• Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking.

  2015cited by this paper
• Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

  2014cited by this paper
• Extracellular traps in lipid-rich lesions of carotid atherosclerotic plaques: implications for lipoprotein retention and lesion progression.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Associations Between HIV Infection and Subclinical Coronary Atherosclerosis

  2014cited by this paper
• Elevated Levels of Circulating DNA and Chromatin Are Independently Associated With Severe Coronary Atherosclerosis and a Prothrombotic State

  2013cited by this paper
• Correlation Between Different Methods to Measure Microbial Translocation and Its Association With Immune Activation in Long-Term Suppressed HIV-1–Infected Individuals

  2013cited by this paper
• Neutrophil recruitment and function in health and inflammation

  2013cited by this paper
• Presence of luminal neutrophil extracellular traps in atherosclerosis

  2012cited by this paper
• Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1.

  2012cited by this paper
• Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals

  2012cited by this paper
• Carotid intima-media thickness in the Spanish population: reference ranges and association with cardiovascular risk factors.

  2012cited by this paper
• The pro- and anti-inflammatory properties of the cytokine interleukin-6.

  2011cited by this paper
• [Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study].

  2011cited by this paper
• Platelets at work in primary hemostasis.

  2011influential reference
• CXC chemokine ligand 4 (Cxcl4) is a platelet‐derived mediator of experimental liver fibrosis

  2010cited by this paper
• Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.

  2009cited by this paper
• Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine.

  2008cited by this paper
• Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review

  2008cited by this paper
• Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.

  2005cited by this paper
• An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas

  2003cited by this paper
• Detection and identification of bacterial DNA in patients with cirrhosis and culture‐negative, nonneutrocytic ascites

  2002cited by this paper

• No citing papers are available for this paper.